Volume 4, Issue 9

New Developments in MS Management

In this issue:

MS may not yet be “curable,” but research continues to improve currently available treatment options and assess the safety and efficacy of new ones. BTK inhibitors, anti-CD20 monoclonal antibodies, the effects of dosing changes and other recent findings are some of the changes that may herald a new age for MS management. 

Join Dr. Jennifer Orthmann-Murphy from the Department of Neurology at the Hospital of the University of Pennsylvania as she explains the most important and most interesting findings in this issue of eMultipleSclerosis Review. 

Learning objectives:

  • Describe how newly approved and emerging therapies for multiple sclerosis may improve outcomes in people with MS. 
  • Discuss new developments in approved therapies for patients with relapsing-remitting multiple sclerosis.  

Author:

Jennifer Orthmann-Murphy, MD, PhD
Jennifer Orthmann-Murphy, MD, PhD

Assistant Professor of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Program Directors:

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: July 7, 2022
Expiration date: July 6, 2024